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The prevalence of pediatric food allergy and anaphylaxis has increased in the last decades, especially in westernized
countries where this emerging phenomenon was marked as a “second wave” of the allergic epidemic. Over recent
years great advances have been achieved in the field of in vitro allergy testing and component-resolved diagnosis
has increasingly entered clinical practice. Testing for allergen components can contribute to a more precise
diagnosis by discriminating primary from cross-reactive sensitizations and assessing the risk of severe allergic reactions.
The basic concept of the management of food allergy in children is also changing. Avoidance of the offending food is
still the mainstay for disease management, especially in primary health care settings, but it severely affects the patients’
quality of life without reducing the risk of accidental allergic reactions. There is a growing body of evidence to show
that specific oral tolerance induction can represent a promising treatment option for food allergic patients. In parallel,
education of food allergic patients and their caregivers as well as physicians about anaphylaxis and its treatment is
becoming recognized a fundamental need. International guidelines have recently integrated these new evidences and
their broad application all over Europe represents the new challenge for food allergy specialists.
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inductionIntroduction
The prevalence of pediatric food allergy (FA) and anaphyl-
axis has increased in the last decades, with westernized
countries experiencing the highest rates. This emerging
phenomenon marked as a “second wave” of the allergic
epidemic has raised concern among the scientific com-
munity, which is currently investigating on potential risk
factors [1-5]. Pediatric allergists are also experiencing re-
markably changes in the pattern of allergic sensitization
and disease manifestations, with a wider range of aller-
genic foods and increase in non-IgE-mediated gastrointes-
tinal disorders [6].
The cornerstone in the diagnostic workup of FA is the
oral food challenge (OFC) which is time and cost-
consuming and involves the risk of adverse allergic
reactions. To this purpose, there is growing interest* Correspondence: diego.peroni@unife.it
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unless otherwise stated.concerning in vitro allergy diagnostic tests to reduce
the need for OFC [7].
FA treatment has also emerged as a developing re-
search field over the past decades. Indeed, the current
management of FA comprises a strict avoidance of trig-
gering foods, which has significant negative impact on
nutritional, psychological and economic status and poses
the risk of developing allergic reactions after accidental
exposure [8].
This review examines the existing relevant literature
focusing on new diagnostic and therapeutic strategies
for FA in children.Search strategy
References were identified by searches of MEDLINE,
PubMed and online Cochrane databases. The terms
searched were food allergy and all of the following,
separately and in combination: diagnosis/treatment/
management/avoidance/anaphylaxis/component-resolved
diagnosis/molecular allergy/oral tolerance/oral immuno-
therapy/oral tolerance induction. We only searched for
English-language original studies, reviews and commentariestral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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lished until November 2014 were included.
Diagnostic procedures are improving through molecular
approaches
According to the current guidelines the basic approach
to diagnosis of FA firstly includes a detailed clinical
history and physical examination, which should drive the
choice of the most appropriate allergy diagnostic tests
[8,9]. Skin prick test (SPT) and serum-specific Immuno-
globulin E (sIgE) for food allergens are the first-line tests
to assess an IgE-sensitization, but their low positive
predictive value makes the elimination diet and OFC ne-
cessary to confirm the diagnosis [10]. OFC, particularly
the double-blind placebo-controlled food challenge, is
still considered the reference standard test for diagnosis
of IgE-mediated and non-IgE-mediated FA [11]. Per-
forming OFC can better define the real prevalence of FA
and improve patients’ quality of life by preventing un-
necessary elimination diet [8]. However, OFCs are costly
and time-consuming, require a specialized setting and
team, and involve the risk of developing severe allergic
reactions, which can be stressful for both patients and
families [12,13].
Several studies have proposed threshold-levels of SPT
and sIgE to predict a positive outcome in OFC [14,15].
Such cut-off values are influenced by the characteristics
of both population examined and methodologies used
and may not be generalizable to other populations, as
recently reviewed by Peters et al. for SPT to egg and
peanut [16]. A recent Dutch study showed that a positive
outcome in OFC can be predicted by using a multivariate
model risk score, which considers the provocative food,
the time between allergen ingestion and development of
symptoms and sIgE level [17]. Over recent years great ad-
vances have been achieved in the search for safe and reli-
able in vitro tests to reduce the need for OFC. To this
purpose, the measurement of sIgE to allergenic molecular
components from allergenic sources, namely component-
resolved diagnosis (CRD), has increasingly entered clinical
practice [18]. CRD can contribute to identify triggering al-
lergens by discriminating primary from cross-reactive
sensitization in poly-sensitized patients. Moreover CRD
can enable the risk assessment of severe allergic reactions
leading to an improved patient management [18].
 Peanut and tree nut allergy - The major peanut
allergen components Ara h 1, Ara h 2 and Ara h 3
are storage protein [19]. Ara h 8 is a member of the
pathogenesis-related protein family (PR-10), which is
relevant to patients with birch pollen allergy [20]. Ara
h 9 is a nonspecific lipid transfer protein (nsLTP) and
has recently been reported to be an important allergen
in the Mediterranean area [21]. Ara h 2 has beenhighlighted as marker of primary sensitization,
persistent allergy and severe reactions [22]. In a
study of 181 French children with suspected peanut
allergy, Ara h 6 and Ara h 2 were the best predictors
of peanut allergy [23]. In a multicentre prospective
study of 210 German children with suspected peanut
or hazelnut allergy, sIgE to Ara h 2 and Cor a 14
resulted more reliable in predicting outcomes in OFC
than sIgE to peanut or hazelnut extracts [24].
Similarly, in a recent Dutch study including 161
hazelnut-sensitized adult and children, sIgE to Cor
a 9 and Cor a 14 were strongly associated with
OFC-proven hazelnut allergy [25]. Among 123
Spanish children with suspected peanut allergy, the
frequencies of sensitization to Ara h 1, Ara h 2,
and Ara h 3 were 60.0%, 72.7% and 43.6% respectively,
with significantly higher sIgE levels in the allergic
group [26]. Among 40 Thai children with peanut
sensitization, sIgE to Ara h 2 was a marker of
anaphylactic reactions, whereas sIgE to Ara h 9
was unrelated to severe reactions [27]. Among 57
Japanese peanut-sensitized children, sIgE to Ara h
2 (cut-off 0.35 kU/l) could discriminate allergic
from tolerant children with a sensitivity of 88% and
a specificity of 84% [28].
 Cow’s milk allergy - Several studies have tried to
determine the serum level cut-off of sIgE to cow’s
milk useful to identify sensitized children who are at
risk of developing allergic reactions to cow’s milk
[14]. Among 123 Brazilian children with cow’s milk
allergy (CMA), testing sIgE to whole cow’s milk
extract (cut-off 3.06 kU/l) was more useful to
diagnose CMA than testing sIgE to α-lactalbumin,
β-lactoglobulin or casein [29]. Finally, SPT with milk
protein may be more reliable than sIgE level in
predicting outcomes in OFC with baked milk
products [30].
 Egg allergy - SPT and sIgE to egg white have been
shown to be a poor predictor of clinical phenotypes
of egg allergy (EA). Among 154 Spanish egg-sensitized
infants with CMA and/or atopic dermatitis without
previous egg consumption, an egg white SPT wheal
reaction of 8 mm and/or sIgE >8.36 KU/l predicted a
positive outcome in OFC of around 94% [31]. Most
children with EA seem to tolerate baked egg, but
tolerance cannot be predicted with conventional
allergy testing. In 186 English children with suspected
EA who underwent an OFC, SPT to egg extract was
slightly better in predicting a positive outcome than
SPT to raw egg [32]. Egg white and yolk contain more
than 20 different glycoproteins and measurement of
sIgE to egg white subcomponents is considered as a
new method for diagnosis [33]. Recently, it has been
shown that sIgE to egg component Gal d 1
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EA compared with sIgE to egg white [34-36]. Moreover
Gal d 1 negative children showed high frequency of
tolerance to boiled egg [37]. In a prospective study of
143 children with EA, SPT to muffin < 2 mm had a
high negative predictive value for baked egg OFC,
whereas ovomucoid SPT 11 mm was very likely to
predict a reaction to baked egg [38]. In 85 Spanish
children sIgG4 to ovoalbumin resulted an independent
predictor of tolerance development to uncooked
egg [39].
 Wheat allergy - sIgE to wheat has poor diagnostic
predictability for wheat allergy. A prospective study
reported that wheat sIgE levels required to identify
subjects with >95% probability of reacting to a
wheat challenge were 80 kUA/L [14]. The
association of sensitization to ω-5-gliadin with
wheat-dependent exercise-induced anaphylaxis (EIA)
is one of the best documented forms of wheat
allergy [40]. A recent study of 108 Finnish children
with suspected wheat allergy, who underwent open
or double-blinded, placebo-controlled oral wheat
challenges identified the “dimeric alpha-amylase
inhibitors 0.19” as a relevant allergen in clinically
reactive participants [41]. Cases of wheat-dependent
EIA with positivity to nsLTP in absence of ω-5-gliadin
sensitization have been reported [42]; thus, patients
with a history consistent with cofactor-enhanced food
allergic anaphylaxis should be tested for sIgE to nsLTP
(e.g. Tri a 14) and to ω-5-gliadin [43].
 Fish and seafood allergy - The major codfish
allergen component, Gad c 1 belongs to a group of
Calcium-transporting muscle proteins known as
parvalbumins. The variable degrees of clinical
cross-reactivity in patients with fish allergy could be
explained by the various degrees of amino acid
homologies ranging from 60% to 80% shared by
parvalbumins [44]. For shellfish allergy, tropomyosin
is the major allergen responsible for cross-reactions
among different species of the shellfish group.
Molecular comparison of tropomyosin from different
crustacean species revealed a very high homology
of up to 98% [44]. It is well known that crustacean
and mollusc allergens do not cross-react with fish
allergens. On the other hand, patients with shellfish
allergy are frequently reported to have allergic reactions
to non-crustacean source, such as house dust mites
and cockroaches. This cross-reactivity is probably
due to the high amino acid homology of
tropomyosins shared by these organisms [45].
Despite CRD revealed to be a useful tool to
highlight in vitro-immunologic cross-reactivity
in seafood allergy, its use in predicting clinical
cross-reactivity is still to be improved. Fruit and vegetable allergy - Pru p 3 is an nsLTP
and considered a major peach allergen component.
In 57 Spanish children suffering from allergic
reactions after eating or having contact with peach,
sIgE to Pru p 3 was detected in 96% of participants
but OFC with peach pulp showed that more than
90% tolerated peeled peach [46]. Allergic reactions
to fruits and vegetables can either result from primary
sensitization to food or to inhalant allergens. In the
latter case triggering foods share similar components
with inhalant allergens causing cross-reactions. A
study performed on 15 subjects from Belgium with
birch pollen allergy and suspected soy allergy, showed
that secondary soy allergy may be responsible for
chronic allergic symptoms (e.g. chronic severe
generalized itching, recurrent urticaria, chronic
diarrhea and generalized atopic dermatitis), besides
typical immediate manifestations (from oral allergic
syndrome up to anaphylaxis). In patients with birch
pollen allergy SPT with soy flour and sIgE to soy
component Gly m 4 were proposed as valuable tools
for the diagnosis of secondary soy allergy [47].
Usually, cross reactivity is attributable to heat-labile
allergens (i.e., PR-10 and profilins) and it is associated
with mild oral reactions. On the contrary heat and
proteolysis-resistant allergens (such as storage
proteins and nsLTP) that primary sensitize through
the oral route are associated with local and systemic
reactions [48].
In a cohort of 30 children with IgE-mediated lentil al-
lergy, initial lentil sIgE level < 4.9 kU/l correlated with
significantly higher likelihood (68.4% vs. 18.2%) of out-
growing the lentil allergy than initial sIgE level ≥ 4.9 kU/l
(p = 0.008). This findings suggests that sIgE levels may
be important for predicting clinical reactivity and per-
sistence of lentil allergy [49]. Reports of allergy to lupin
are increasing with the diffusion of the lupin flour
consumption in bakery due to primary sensitization or
cross-reactions with other legumes. In a group of 12
Italian children allergic to peanut, b-conglutin has
been identified as the major lupin allergen causing
in vitro and in vivo cross-reactivity with peanut com-
ponents [50].
Despite the CRD shows promise in reducing the need
for OFC, there are circumstances in which OFC remains
the only reliable method to ascertain the diagnosis of
FA, such as cases of suspected food-dependent EIA with
discordant medical history and sIgE results [51], or cases
of suspected food protein-induced enterocolitis syn-
drome (FPIES), a non-IgE mediated FA in which in vivo
and in vitro allergy tests show poor diagnostic accuracy.
An OFC may not be necessary to diagnose FPIES only
in very indicative cases (i.e. two or more acute episodes
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prompt resolution after avoidance of the causative
food) [9].
Food avoidance
Avoidance of the offending food and emergency treat-
ment of adverse reactions are currently the mainstays
for the management of IgE-mediated and non-IgE-
mediated FA [8]. A dietary programme for FA should
always include education on how to avoid specific aller-
gens as well as comprehensive nutrition assessment on
how to appropriately substitute foods in order to obtain
adequate energy intake and nutrients for age [52]. Indeed,
food avoidance poses the risk of malnutrition and nutrient
deficiency in growing allergic children [53]. There is evi-
dence that children with FA present a decreased weight-
for-age and height-for-age compared to healthy subjects.
Growth differences in children with FA are evident despite
an appropriate caloric intake and correlate with the num-
ber of foods avoided and duration of the diet [54,55]. A
recent US cross-sectional study confirmed a poor growth
in children with FA (IgE- and non-IgE-mediated) supple-
mented with amino-acid formula, despite an adequate
daily energy intake [56]. The mechanisms responsible for
growth differences in children with FA are still unclear.
Risk factors which may lead to growth deficit in such
category of children seem to be the early onset of the
disease, multiple food allergies, elimination of foods
with high nutritional value (e.g. cow’s milk and egg) and
subclinical intestinal inflammation with increased intes-
tinal permeability [53]. In a recent prospective study
conducted in 131 food allergic children on a restricted diet
for cow’s milk and egg, about one-third of asymptomatic
participants showed elevated intestinal permeability [57].
Another aspect that must be considered is that dietary
elimination significantly affects the quality of life of aller-
gic children and their families due to social restriction
and risk of accidental reactions [58-60]. A Canadian
study reported an annual incidence rate of 12.5% of
accidental exposure to peanut in allergic children, with
higher risk for adolescents and cases with recent diagno-
sis [61]. Questionnaires-based surveys on food allergic
patients ‘quality of life addressed at different age groups,
showed that food avoidance correlate with anxiety about
an accidental adverse reaction [62,63]. Social occasions,
trips and even only playing at friends’ houses are consid-
ered dangerous settings by parents of allergic children
[64]. Shopping is considered a difficult activity because
of the need to identify ingredients on food labels [52]. A
restricted diet can even results in an economic burden
for the family budget, especially in infants requiring
amino-acid formula supplementation [65].
Finally, it must be considered that FA tends to resolve
in most cases during the first years of life. Therefore therequired period of strict elimination diet is not a priori
established and periodical re-evaluations by the allergist
are fundamental to assess the changing nutritional needs
and eventually resolution of the disease.
Specific oral tolerance induction: a promising alternative
treatment
Over the last two decades, alternative treatment strategies
have been investigated for FA, mainly targeting foods that
commonly trigger IgE-mediated FA in children (i.e. cow’s
milk, egg and peanut) [66]. As FA develops as a result of
failure or loss of oral tolerance to food allergens, one of
the most promising therapeutic approach pursued is oral
immunotherapy or specific oral tolerance induction
(SOTI) [67]. SOTI consists in oral assumption of increas-
ing doses of the relevant allergen performed in controlled
setting; this build-up phase is followed by a daily regular
assumption of the tolerated dose which typically occurs at
home. The aim is to induce an immune modulation in
order to achieve a permanent oral tolerance [68].
There is a growing body of literature to show that
SOTI is effective in increasing the threshold of reactivity
for the most common triggering foods. This process,
also referred as “desensitization”, can confer protection
against accidental allergic reactions and can contribute
to improve nutritional status and quality of life [69-79].
In a recent controlled trial conducted by Dello Iacono
et al., 20 children with severe hen’s EA were equally
randomized to receive SOTI with raw hen’s egg emul-
sion or egg-free diet for 6 months. At the end of the
study period 90% of the SOTI group achieved partial tol-
erance, whereas sensitivity to raw hen's egg remained
unchanged in 90% of controls [70]. Longo et al. reported
that SOTI was effective in desensitizing a significant
percentage of children with very severe CMA and high
levels of sIgE [71]. Staden et al. investigated the efficacy
of SOTI in comparison with the elimination diet in chil-
dren with CMA or hen’s EA. At the follow-up challenge
36% in the SOTI group showed permanent tolerance,
12% were tolerant with regular intake and 16% were par-
tial tolerant, whereas only 35% developed tolerance in
the control group [72].
An open point of discussion is whether SOTI induces
persistent tolerance or transient desensitization which
may need regular allergen intake to be maintained [80].
Recent evidence suggests that SOTI to milk, egg and
peanut can result in sustained unresponsiveness to
those foods after discontinuing the maintenance dose,
but more research into the long-term outcomes of
SOTI is needed [76-79]. The immunological mechanisms
underlying SOTI are currently unknown and their under-
standing could address the issue regarding long-term
response to this treatment [68]. Fuentes-Aparicio et al. re-
ported that acquisition of tolerance after SOTI in hen’s
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effector-memory CD4+ T-cell population and an in-
crease in a hypo-proliferative subset of CD4+ T-cell
population. This subset could represent a marker of
tolerance induction [81]. Additionally, Vila et al. showed
that the development of clinical tolerance to egg through
SOTI is associated with a decrease in the mean sIgE level
and in the antigen-specific basophil responsiveness [82].
Despite SOTI has demonstrated efficacy for clinical
desensitization, one of the major concern is its safety.
Adverse reactions occurring during SOTI are usually mild
to moderate, predominantly oropharyngeal and easy to
manage, but systemic severe events have been reported
[83]. Therefore SOTI has still to be considered an experi-
mental treatment belonging to the contest of clinical trials
and further research is needed to establish its long-term
efficacy, safety and cost-effectiveness [67]. An emerging
strategy and possible alternative to SOTI for the treatment
of IgE-mediated CMA and EA is the use of extensively
heated forms of these allergens, such as in baked products.
Recent studies have shown that the majority of children
with CMA and EA tolerated baked milk or egg during an
OFC and safely incorporated these products into their diet
[34,84]. Tolerance of baked milk or egg is considered a
marker of transient IgE-mediated FA [85].Anaphylaxis treatment
Prompt administration of intramuscular epinephrine is
the first-line therapy for food-induced anaphylaxis [8].
Maintaining access to an adrenaline auto-injectors (AAI)
as well as using an AAI are essential steps for an effect-
ive management of IgE-mediated FA [86]. First, it has to
be decided who should be prescribed an AAI. However
there are still no generally valid indication criteria for
prescribing an AAI [87]. Johnson et al. showed the pre-
scription practice of an AAI were very variable among
pediatricians. The most influencing factors included pea-
nut or tree nut allergy and parental anxiety [88]. So, as
long as there are no improved anaphylaxis guidelines, the
indication should be given individually considering the
medical history and family’s needs [89]. The next step is
defining when epinephrine should be used. The best
outcome is provided when epinephrine is given as soon
as early symptoms of anaphylaxis occur [87]. Hence, the
focus should lie on early recognition of symptoms to
promptly use the AAI. To this purpose Jacobs et al. con-
ducted a survey to investigate the recognition and treat-
ment of first initial food allergic reactions. They
detected that only one-third of the initial reactions with
symptoms likely to represent anaphylaxis were recog-
nized and treated with epinephrine. Remarkably, only
half of these patients treated with epinephrine were pre-
scribed an AAI [90].H1-antihistamines have long been used for mild, iso-
lated, non-progressive cutaneous reactions to help re-
lieving pruritus, hives, angioedema and conjunctivitis.
However, H1- and H2-receptor antagonists cannot be
used as substitute for epinephrine, but only as adjunctive
medications during anaphylaxis [91]. In a recent EAACI
systematic review on FA management, it has been reported
a weak evidence (level of evidence III, grade C) to support
the benefits of H1 antihistamines for children and adults
with acute non-life-threatening symptoms of FA [8].
However no evidence for efficacy of antihistamines in
the treatment of more severe symptoms was reported.
Furthermore, the prophylactic administration of antihis-
tamines can early mask symptoms of anaphylaxis and
lead to delayed treatment of dangerous reactions with
epinephrine. Inhaled beta-2 adrenergic agonists have
been used for the relief of cough and wheezing in
addition to epinephrine, but are not a substitute for epi-
nephrine [91]. Oral or intravascular corticosteroids are
often administered during an acute reaction to prevent
protracted or biphasic episodes of anaphylaxis. Other
interventions include supplemental oxygen and fluids
which may be considered after the administration of
epinephrine depending on the patient’s symptoms [92].
A recent Cochrane review was unable to identify rele-
vant studies with evidence for the use of corticosteroids
in anaphylaxis [93].
Conclusion
The management of FA in children is improving through
the acquisition of new knowledge in the field of diagnosis
and treatment. CRD and SOTI are being intensively investi-
gated. Their implementation in routine clinical practice can
offer new perspectives in the management of patients with
FA. In parallel, education of physicians and food allergic pa-
tients about anaphylaxis and its treatment is becoming rec-
ognized as an unmet need. The recent integration of all this
new knowledge in international guidelines was a great
achievement. The broad implementation of these guidelines
all over Europe is now the new challenge for specialists, pa-
tients and other stakeholders of FA.
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